Omalizumab for the Treatment of Inadequately Controlled Allergic Rhinitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Abstract
Background Patients with moderate-to-severe allergic rhinitis who are inadequately controlled despite treatment according to current rhinitis management guidelines have a significant unmet medical need. Such patients have a negative impact on daily functioning and are at risk of developing serious comorbidities, such as asthma and chronic rhinosinusitis. Objective To assess the efficacy and safety of omalizumab in poorly controlled allergic rhinitis under a meta-analysis framework. Methods MEDLINE and the Cochrane Central Register of Controlled Trials were searched through September 2013. Studies on the efficacy of omalizumab in allergic rhinitis that assessed clinical outcomes were selected. Descriptive and quantitative information was extracted; mean differences and relative risk estimates were synthesized under a fixed or random effects model. Heterogeneity was assessed by using the Q statistic and the I(2) metric. Subgroup analyses were performed for the presence of specific immunotherapy treatment. Results Of the 352 citations retrieved, 11 studies of 2870 patients were finally included. A statistically significant reduction in the daily nasal symptom severity score (standardized mean difference -0.67 [95% CI, -1.3 to -0.31]; P Conclusions Omalizumab is statistically significantly associated with symptom relief, decreased rescue medication use, and improvement of quality of life in patients with inadequately controlled allergic rhinosinusitis.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Omalizumab is efficacious in allergic rhinitis.
“Omalizumab (free anti-IgE) has demonstrated its efficacy in AR [179], although it is not authorized for this disease.”
From Position Paper on Nasal Obstruction: Evaluation and Treatment (2018) · cites this paper as [179]
Cites
Quantitative Synthesis in Systematic Reviews
Lau, J., Ioannidis, J. P. A., & Schmid, C. H. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-9-199711010-00008 · Cited by 2,517 · see citing works
Casale, T. B., Busse, W. W., Kline, J. N., Ballas, Z. K., Moss, M. H., Townley, R. G., Mokhtarani, M., Seyfert-Margolis, V., Asare, A., Bateman, K., et al. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.09.036 · Cited by 355 · see citing works
Kopp, M. V., Hamelmann, E., Zielen, S., Kamin, W., Bergmann, K. ‐., Sieder, C., Stenglein, S., Seyfried, S., Wahn, U., & for the DUAL study group (2009) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2008.03121.x · Cited by 181 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926 · see citing works
International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
Wise, S. K., Lin, S. Y., Toskala, E., Orlandi, R. R., Akdis, C. A., Alt, J. A., Azar, A., Baroody, F. M., Bachert, C., Canonica, G. W., et al. (2018) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22073 · Cited by 557 · see citing works
Chan, S., Cornelius, V., Cro, S., Harper, J. I., & Lack, G. (2020) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2019.4476 · Cited by 130 · see citing works
Position Paper on Nasal Obstruction: Evaluation and Treatment
SEAIC Rhinoconjunctivitis Committee & SEORL Rhinology, A., Valero, A., Navarro, A., del Cuvillo, A., Alobid, I., Benito, Jr., Colás, C., de los Santos, G., Fernández Liesa, R., García-Lliberós, A., et al. (2018) · Journal of Investigational Allergology and Clinical Immunology · doi:10.18176/jiaci.0232 · Cited by 76 · see citing works
Novel Biologicals for the Treatment of Allergic Diseases and Asthma
Tan, H.-T. T., Sugita, K., & Akdis, C. A. (2016) · Current Allergy and Asthma Reports · doi:10.1007/s11882-016-0650-5 · Cited by 68 · see citing works
- Authors
- Tsabouri, S., Tseretopoulou, X., Priftis, K., & Ntzani, E. E.
- Affiliations
- University of Ioannina (GR)
- National and Kapodistrian University of Athens (GR)
- Corresponding author
- Ntzani, Evangelia E.
- Venue
- The Journal of Allergy and Clinical Immunology: In Practice
- Publisher
- Elsevier BV
- Published
- 2014-05
- Volume
- 2
- Issue
- 3
- Pages
- 332-340.e1
- ISSN
- 2213-2198 (ISSN-L)
- OpenAlex
- W2163851897
- Cited by
- 151
- References
- 3
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 9 · 2023: 10 · 2022: 13 · 2021: 16 · 2020: 16 · 2019: 17 · 2018: 15 · 2017: 6 · 2016: 15 · 2015: 11 · 2014: 9
- FWCI
- 1.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Allergy and Clinical Immunology In Practice (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
- Health Sciences › Medicine › Physiology › Asthma and respiratory diseases
- Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
- Keywords
- omalizumab, allergic rhinitis, anti-IgE therapy, nasal symptom severity, rescue medication use, adverse events, quality of life, allergic rhinosinusitis, allergen immunotherapy
- MeSH terms
- Omalizumab, Adult, Antibodies, Anti-Idiotypic, Child, Desensitization, Immunologic, Female, Humans, Male, Randomized Controlled Trials as Topic, Treatment Outcome, Anti-Allergic Agents, Antibodies, Monoclonal, Humanized, Rhinitis, Allergic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
